Related Experiment Video

Updated: Jun 7, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ticlopidine does not reduce in vivo platelet thromboxane biosynthesis and metabolism in diabetic patients

S Rotondo1, C Cerletti, G Gaetano

  • 1Laboratory of Platelet and Leukocyte Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, 66030, Santa Maria Imbaro.

Platelets
|November 4, 2010
PubMed

Insights

Diabetic patients with cardiovascular issues show no change in urinary 11-dehydro-thromboxane levels after ticlopidine treatment. This suggests urinary 11-dehydro-TXB(2) may not reliably monitor antiplatelet drug effectiveness in diabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic patients face elevated cardiovascular complication risks.
  • Platelet role in diabetic vascular complications remains unclear: cause or consequence?
  • Urinary 11-dehydro-thromboxane (11-dehydro-TXB2) is a proposed marker for in vivo platelet activation.

Purpose of the Study:

  • To investigate the effect of ticlopidine, a non-cyclo-oxygenase inhibiting antiplatelet agent, on urinary 11-dehydro-TXB2 excretion.
  • To assess the reliability of urinary 11-dehydro-TXB2 as a marker for monitoring ticlopidine's antiplatelet activity in diabetic patients with macrovascular complications.

Main Methods:

  • Study included diabetic patients with macrovascular complications.
  • Ticlopidine was administered as an antiplatelet treatment.
  • Urinary 11-dehydro-TXB2 levels were measured before and after ticlopidine treatment.

Main Results:

  • Urinary 11-dehydro-TXB2 excretion levels did not significantly change after ticlopidine treatment compared to pre-treatment values.
  • This indicates a lack of measurable effect of ticlopidine on this specific biomarker in the studied population.

Conclusions:

  • Urinary 11-dehydro-TXB2 may not be a reliable biomarker for monitoring the in vivo antiplatelet activity of ticlopidine.
  • The findings suggest limitations in using urinary 11-dehydro-TXB2 for assessing drugs that do not directly impact arachidonic acid metabolism in diabetic patients.

More Related Videos

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...